A Phase I/II Study of NBTXR3 Activated by Radiation Therapy (SABR) for Patients with Non-Small Cell Lung Cancer or Head and Neck Squamous Cell Carcinoma Cancer Treated with an Anti-PD1 Antibody (Nivolumab or Pembrolizumab)- First Nanobiotix immuno-oncology trial will be conducted in the U.S.- Multi-arm trial targets sub-population of advanced and...